Literature DB >> 227585

Prolactin receptors in human breast cancer cells in long-term tissue culture.

R P Shiu.   

Abstract

Prolactin receptors have been identified for the first time in a number of human breast cancer cell lines and a normal human breast cell line maintained in long-term tissue culture. Optimal conditions for determining the binding of 125I-labeled human prolactin to these cells were established. Five different tumor cell lines have different content of prolactin receptors ranging from 2,300 to 26,000 sites/cell. All tumor cell lines contained more prolactin receptors than does one normal breast cell line (1700 sites/cell). The prolactin receptors in these human mammary tumor cells not only bind human prolactin but also recognize other lactogenic hormones such as human growth hormone, human placental lactogen, and sheep prolactin, but not animal growth hormone, which are not lactogenic. The affinity (Ka) of binding of human prolactin to these cells is 4 x 10(9) M-1 (Kd = 2.5 x 10(-10)M). The hormone specificity and affinity for hormone of these human mammary tumor cells are very similar to that found for the rabbit mammary gland. These human mammary tumor cell lines in long-term culture should prove very useful to study the biology of prolactin receptors in living human cells and the role of prolactin in the tumorigenesis of the human breast.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 227585

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Serum and liver cytosolic growth-hormone-binding proteins are antigenically identical with liver membrane 'receptor' types 1 and 2.

Authors:  R Barnard; M J Waters
Journal:  Biochem J       Date:  1986-08-01       Impact factor: 3.857

2.  Structure and expression of the guinea-pig alpha-lactalbumin gene.

Authors:  J E Laird; L Jack; L Hall; A P Boulton; D Parker; R K Craig
Journal:  Biochem J       Date:  1988-08-15       Impact factor: 3.857

3.  Elevated insulin receptor content in human breast cancer.

Authors:  V Papa; V Pezzino; A Costantino; A Belfiore; D Giuffrida; L Frittitta; G B Vannelli; R Brand; I D Goldfine; R Vigneri
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

4.  Prolactin stimulates the JAK2 and focal adhesion kinase pathways in human breast carcinoma T47-D cells.

Authors:  E Canbay; M Norman; E Kilic; V Goffin; I Zachary
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

5.  Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice.

Authors:  H Wennbo; M Gebre-Medhin; A Gritli-Linde; C Ohlsson; O G Isaksson; J Törnell
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

Review 6.  Regulation of prolactin receptor levels and activity in breast cancer.

Authors:  G Swaminathan; B Varghese; S Y Fuchs
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-19       Impact factor: 2.673

7.  Influence of estradiol on the total uptake and incorporation of thymidine in human breast cancer (MCF-7) in long-term cell culture. Comparison of autoradiographic and biochemical methods.

Authors:  R Coosen; P W de Jong; F Schwarz
Journal:  Mol Cell Biochem       Date:  1982-02-19       Impact factor: 3.396

8.  Determination and properties of proteohormone receptors in malignant gynecological tumors with special reference to lactogen receptors in human breast cancer.

Authors:  H G Bohnet
Journal:  Arch Gynecol       Date:  1980

9.  Effect of hormones on dissociation of prolactin from the rabbit mammary gland prolactin receptor.

Authors:  S Sakai
Journal:  Biochem J       Date:  1991-10-15       Impact factor: 3.857

10.  Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2.

Authors:  K C Leung; N Doyle; M Ballesteros; K Sjogren; C K W Watts; T H Low; G M Leong; R J M Ross; K K Y Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.